Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News > Health News
Audio By Carbonatix
4:05 PM on Thursday, December 18
The Associated Press
HAYWARD, Calif.--(BUSINESS WIRE)--Dec 18, 2025--
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14 th, 2026, at 3:00 pm PT.
A live webcast of the presentation will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251218075951/en/
CONTACT: Investor Inquiries
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
[email protected] Inquiries
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
[email protected] Bassiri
AD, Corporate Communications
(510) 406-8520
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Arcus Biosciences
Copyright Business Wire 2025.
PUB: 12/18/2025 04:05 PM/DISC: 12/18/2025 04:05 PM
http://www.businesswire.com/news/home/20251218075951/en